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Abstract
Background: Mali is endemic for all five targeted major neglected tropical diseases (NTDs). As one of the five ‘fast-track’
countries supported with the United States Agency for International Development (USAID) funds, Mali started to integrate
the activities of existing disease-specific national control programs on these diseases in 2007. The ultimate objectives are to
eliminate lymphatic filariasis, onchocerciasis and trachoma as public health problems and to reduce morbidity caused by
schistosomiasis and soil-transmitted helminthiasis through regular treatment to eligible populations, and the specific
objectives were to achieve 80% program coverage and 100% geographical coverage yearly. The paper reports on the
implementation of the integrated mass drug administration and the lessons learned.
Methodology/Principal Findings: The integrated control program was led by the Ministry of Health and coordinated by the
national NTD Control Program. The drug packages were designed according to the disease endemicity in each district and
delivered through various platforms to eligible populations involving the primary health care system. Treatment data were
recorded and reported by the community drug distributors. After a pilot implementation of integrated drug delivery in
three regions in 2007, the treatment for all five targeted NTDs was steadily scaled up to 100% geographical coverage by
2009, and program coverage has since been maintained at a high level: over 85% for lymphatic filariasis, over 90% for
onchocerciasis and soil-transmitted helminthiasis, around 90% in school-age children for schistosomiasis, and 76–97% for
trachoma. Around 10 million people have received one or more drug packages each year since 2009. No severe cases of
adverse effects were reported.
Conclusions/Significance: Mali has scaled up the drug treatment to national coverage through integrated drug delivery
involving the primary health care system. The successes and lessons learned in Mali can be valuable assets to other
countries starting up their own integrated national NTD control programs.
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Introduction
Neglected tropical diseases (NTDs) are a group of diseases that
affect the most vulnerable and the poorest group of the
populations in the world [1,2]. The World Health Organization
(WHO) recommends five public health strategies for the
prevention and control of the NTDs: preventive chemotherapy
(PCT); intensified case management; vector control; provision of
safe water, sanitation and hygiene; and veterinary public health
[1]. The major NTDs currently being targeted through PCT
include lymphatic filariasis (LF), onchocerciasis, schistosomiasis,
soil-transmitted helminthiasis (STH, including ascariasis, hook-
worm infection and trichuriasis) and trachoma. These five major
NTDs cause high disease burden with severe disfigurement,
disability and blindness, blighting the lives of more than one billion
people worldwide and threatening the health of millions more [1].
The drugs needed for these five NTDs are robust, safe, low-cost
and available by donation from the pharmaceutical companies or
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the target populations either alone or in combination to prevent
morbidity caused by these NTDs, or in some cases, to eliminate
the diseases [4,5].
Mali is landlocked in West Africa with a population of 15.5
million. It is divided into eight administrative regions (Kayes,
Koulikoro, Sikasso, Segou, Mopti, Tombouctou, Gao and Kidal)
and Bamako. The northern part of the country extends deep into
the Sahara desert and the southern region features the Niger and
Senegal rivers, where the majority of the country population
inhabits. The country’s economy centers on agriculture and
fishing. Mali is one of the poorest countries in the world and
ranked 160 out of 169 countries according to the Human
Development Report 2010 [6]. It is endemic with all five major
NTDs [7–11]. Control of the NTDs before 2007 was through four
independent vertical national programs under the Ministry of
Health (MoH): the National Onchocerciasis Control Program
(PNLO), the National Lymphatic Filariasis Elimination Program
(PNEFL), the National Schistosomiasis and Soil-Transmitted
Helminths Control Program (PNLS) and the National Blindness
Prevention Program (PNLC).
Onchocerciasis was originally prevalent in five regions in the
country, including Kayes, Koulikoro, Sikasso, Segou and Mopti,
and the PNLO was established in 1986 to address the public
health implications of the disease. The eastern part of the endemic
regions (Koulikoro rive droite, Sikasso, Se ´gou and Mopti) was
included in the original program area of the Onchocerciasis
Control Program (OCP). In 2002 onchocerciasis was declared
eliminated as a public health program in large parts of these areas
with only epidemiological and entomological surveillance con-
tinuing to monitor the prevalence and microfilarial load in the
population and to also monitor the infectivity of the vector
Simulium damnosum. The western part of the endemic regions
(Kayes and Koulikoro rive gauche) was included in the western
extension of OCP in 1987 with ivermectin (IVM, donated by
Merck & Co.) administration and later with Community Directed
Treatment with Ivermectin (CDTI) with support from the African
Program for Onchocerciasis Control (APOC) and using the
community drug distributors (CDDs). The disease is currently
endemic in 17 districts (Sikasso, one of the original 16 districts, was
split into two separate districts in 2010) in three regions in Kayes,
Koulikoro and Sikasso.
LF, caused by Wuchereria bancrofti, is endemic throughout Mali
[10,12] with the entire population being at risk of disease. The
PNEFL was established in 2004 and subsequently a national
mapping survey was carried out using Immunochromatographic
Test cards confirming LF endemicity across Mali (Dembe ´le ´,
unpublished data). The MDA for LF started in 2005 in four of the
five onchocerciasis districts in Sikasso using CDTI plus albenda-
zole (ALB, donated by GlaxoSmithKline), with support from the
Government of Mali.
Both urogenital (caused by Schistosoma haematobium) and intestinal
(caused by S. mansoni) forms of schistosomiasis are present in the
country [13]. Two national surveys were conducted with the first
in 1984–1989 and the second in 2004–2006 [7,14,15]. The results
confirmed presence of schistosomiasis throughout the country with
geographically varying degrees of prevalence. The later survey in
2004–2006 showed a prevalence of 38.3% (ranging 0.0–99.0%) for
S. haematobium and 6.7% (ranging 0.0–94.9%) for S. mansoni [15].
Schistosomiasis control in Mali was initiated in the Bandiagara
district, Mopti as a component of a dam-building project in 1978
and became a national program (PNLS) in 1982 [13,15]. The
initial control program with praziquantel (PZQ) distribution was
implemented by the MoH in collaboration with WHO and with
support from the German Technical Co-operation [13], but the
MDA ceased later due to lack of further funding. In 2005, the
MDA resumed with support from the Schistosomiasis Control
Initiative (SCI) with PZQ procured from certified generic
manufacturers, targeting school-age children and at-risk adults
with PCT through school-based and community-based drug
delivery in all endemic regions and Bamako (school-age children
only) [16,17].
STH is a public health problem throughout Mali. The national
survey in 2004–2006 (together with schistosomiasis) in school
children from 7–14 years of age showed that the whole country is
endemic for STH, with prevalence of up to 34.3% with hookworm
infection (in Yorosso, Sikasso) (R Dembe ´le ´, unpublished data).
STH control consists of several drug delivery platforms in Mali.
The National Intensified Nutrition Weeks (SIAN, French
acronym) deliver vitamin A and ALB twice a year to children of
12–59 months and to women immediately post-partum. In 2004,
the PNLS was expanded to include STH, and ALB was delivered
at the same time through school-based and community-based drug
delivery to those receiving PZQ treatments for schistosomiasis
during 2005–2007 with the support from the Schistosomiasis
Control Initiative. The population above 5 years also benefits from
annual treatment with ALB and IVM from the LF elimination
program.
Trachoma as a blinding disease is found in all districts of the
eight regions of the country (except Bamako). A national survey in
all regions except Bamako was conducted in 1996–1997 [11]. The
prevalence of active trachoma, follicular (TF) or intense (TI), was
estimated to be 34.9% among children under 10 years of age, and
the prevalence of trichiasis among women over 14 years of age was
2.5%, and 1% had central corneal opacity [11]. The PNLC
initiated a trachoma control program in 1998 following the
national survey adopting the WHO recommended SAFE
(Surgery, Antibiotics, Facial washing and Environmental improve-
ment) strategy [18,19], benefiting from the Zithromax (ZTM)
donation program by Pfizer Inc. Significant progress had been
achieved in trachoma control since the start of the national
program [19–21].
Author Summary
Neglected tropical diseases (NTDs) are a group of chronic
infections that affect the poorest group of the populations
in the world. There are currently five major NTDs targeted
through mass drug treatment in the affected communities.
The drug delivery can be integrated to deliver different
drug packages as these NTDs often overlap in distribution.
Mali is endemic with all five major NTDs. The integrated
national NTD control program was implemented through
the primary health care system using the community
health center workers and the community drug distribu-
tors aiming at long-term sustainability. After a pilot start in
three regions in 2007 without prior examples to follow on
integrated mass drug administration, treatment for the five
targeted NTDs was gradually scaled up and reached all
endemic districts by 2009, and annual drug coverage in
the targeted population has since been maintained at a
high level for each of the five NTDs. Around 10 million
people received one or more drug treatments each year
since 2009. The country is on the way to meet the national
objectives of elimination or control of these diseases. The
successes and lessons learned in Mali are valuable assets to
other countries looking to start similar programs.
Neglected Tropical Disease Control in Mali
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States Agency for International Development (USAID) NTD
Control Program managed by RTI International [22], Mali
launched the integrated national NTD Control Program
(NTDCP) in 2007 with technical assistance initially from
International Trachoma Initiative (ITI, 2007) and then from
Helen Keller International (HKI) from 2008 onward. The overall
objectives of the Mali’s NTD control program are to eliminate LF,
onchocerciasis and trachoma as public health problems and to
reduce morbidity caused by schistosomiasis and STH through
regular mass drug administration (MDA), with specific objectives
of achieving 80% program coverage and 100% geographical
coverage yearly within the five-year program plan. This current
paper serves as a report on the progress made by the integrated
national NTDCP in Mali, drawing from objectives achieved,
documented experiences and pertinent lessons learned of the
program from 2007 to 2011, and focusing on only aspects of
integrated MDA activities.
Methods
The national integrated NTD Control Program
The existing disease-specific vertical national programs
achieved various degrees of coverage throughout the country
and mapping of distribution of each NTD was almost complete
before integration. These disease-specific national control pro-
grams already achieved significant success before 2007 as
described in the introduction. Integration of control activities on
certain diseases already occurred, e.g. onchocerciasis and LF, and
schistosomiasis and STH, on co-delivery of drugs. Building on
these successes, in 2007 Mali began to further integrate the
existing disease-specific control programs to increase efficiency
and program coverage for each target disease. The USAID funds
support all the integrated PCT-related activities and procurement
of PZQ. Although the integrated NTD control program include
other non-MDA components, this paper focuses on the imple-
mentation of MDA component only.
Leadership
The NTDCP is led by the MoH through the National
Directorate of Health. The National Steering Committee of the
program was established and is chaired by the National Director
of Health and its members include members of the Technical
Coordinating Committee (TCC, described below), the Head of
Planning, Training and Health Information Unit, the Head of
Public Health and Safety Division, the Head of the Nutrition
Division, the Dean of the Faculty of Medicine, Pharmacy and
Odonto-Stomatology (FMPOS), and the representatives of non-
governmental developmental organization (NGDO) partners. The
Steering Committee meets twice a year to discuss the progress of
the program and issues arising.
A National Strategic Plan for integrated control of NTDs
(2007–2011) was developed in 2007 as the blueprint to direct the
control activities. A new five-year national strategic plan (2012–
2016) is being updated and finalized.
Program coordination
Under the National Directorate of Health, Division of Disease
Control and Prevention (DPLM) is responsible for coordinating
the activities of control and elimination of priority diseases in Mali.
The existing four disease-specific national control programs are
under the remit of DPLM, which provides an ideal framework for
coordination of integrated NTD control activities. The dedicated
NTD coordinator at HKI works closely with the four National
Coordinators of the disease-specific control programs to facilitate
the integrated activities.
Under the DPLM, the TCC was established and is chaired by
the Chief of DPLM, comprising four National Coordinators of the
disease-specific control programs, the Head of Nutrition Division,
the representative from the National Public Health Research
Institute, the representative from the National Center of
Information, Education and Communication for Health
(CNIECS), and the representative of the grantee NGDO (initially
ITI and currently HKI). This committee meets every quarter. The
program review and planning workshop was conducted annually
to review the progress and to plan for the coming year, attended
by the TCC members, the Regional Health Directors, and the
regional NTD focal persons. The Regional Health Teams in turn
planned the MDA activities for each district with the District
Health Teams. In Mali, community health centers play a very
important role in providing primary health care at local level.
Within each district, there are a number of community health
centers, each responsible for a number of villages. For long-term
sustainability and local capacity building, the NTD control
activities were integrated into the primary health care system at
local level. Community health center workers (CHCWs) play an
important role in the program as their routine health care
activities. These CHCWs provided training and supervision of
CDDs, and were responsible for drug allocation, treatment data
collation in their catchment area, and data reporting to the district
health officers. Figure 1 shows the structure of the program.
Implementation strategies
To integrate the PCT activities of each existing control
program, a situation analysis was conducted to map out the
overlaps of the disease distribution in each district using the
existing disease distribution data. Figure 2 shows the overlapping
distributions of the five targeted NTDs in each districts of the
country. The PCT strategy for each disease in each district was
decided according to the known prevalence of the disease in the
district and the WHO PCT guidelines [4].
Drug packages for each district were determined as shown in
Figure 3 according to the disease distribution shown in Figure 2
above and the WHO PCT guidelines. There was insufficient
evidence and hence lack of clear guidance for combinations of
available drugs, therefore, to avoid possible side effects due to
combination, different drug packages were delivered in sequential
fashion with one week between deliveries, where two or more drug
packages were required. For example, where all three packages
wererequired,MDAwas organized as ZTMfor week 1,ALB/IVM
for week 3 and PZQ for week 5. This was also to avoid confusion
among the CDDs with managing different dose poles at the same
time, considering the relatively low education level in Mali villagers.
Several successful strategies for drug delivery were used by
existing disease-specific national control programs, e.g. CDTI for
onchocerciasis and LF, school-based and community-based drug
delivery for schistosomiasis and STH, and community-based drug
delivery for trachoma. Each of these was operating in disease-
specific program areas. To scale up each program to a national
coverage in the integrated control program, the four existing
national programs worked together to plan and coordinate the
MDA activities. A number of drug delivery strategies were used in
combination in districts to deliver the drug packages by the trained
CDDs: 1) School-based distribution by trained school teachers,
taking place in schools targeting school-going children; 2)
Community-based distribution by CDDs, including door-to-
door/household distribution, focal distribution in the market,
mosque, or other busy places, and mobile distribution through
Neglected Tropical Disease Control in Mali
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particularly in nomadic zones; and 3) Health center distribution by
CHCWs, taking place at the health centers. Before MDA, in
villages the trained CDDs work together with village chiefs to
register the target population including name, age and sex. They
receive drug allocations from community health centers according
to the estimated population in each village and take the drugs to
the village. CDDs, village chiefs and CHCWs discuss to decide the
best drug delivery strategies for each village, mainly using
community-based door-to-door distribution and if MDA happens
during school terms, school-based distribution as well. In cities/
towns, all the above mentioned three strategies are normally used.
During MDA, CDDs distribute drugs according to the registered
list, and they first confirm that the person has not been treated
before treating him/her. The drugs administered are recorded in
the register. MDA normally takes 2–3 days in each village.
Extensive advocacy was conducted before each round of MDA
and sufficient information was given to the general public about
the national program. The drugs were voluntarily taken by the
persons targeted in the endemic districts.
Training and drug distribution
CDDs in each village were selected by the village and the
management team of the community health center, and were used
in the program to conduct the MDA activities in communities.
The criteria for CDDs include: they were respected by the
community; they had ability to read and write; and they were
available during the MDA campaigns.
Figure 1. The NTD control program coordination structure in Mali.
doi:10.1371/journal.pntd.0001574.g001
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out throughout the implementation areas. The training sessions
started at the regional level and cascaded down to the community
level. Training of trainers was organized in the regions and these
trainers subsequently trained the CHCWs (as supervisors) at the
district level. The supervisors then trained the CDDs at the
community health centers. Refresher training was also provided
for supervisors and CDDs each year before the MDA campaign
started. Table 1 shows the number of people trained or retrained
from 2007 to 2011. In view of the usually low educational level of
Mali villagers, the NTDCP decided to train the CDDs in the drug
administration before each treatment round with different drug
packages in order to avoid confusion in CDDs to calculate and
administer the drugs using different dose poles. As the national
program has matured and in efforts to reduce costs and streamline
the program, integrated training is now being introduced. In total,
86,248 persons have so far been trained and retrained across the
country.
Advocacy and community mobilization
Advocacy activities undertaken aimed to promote country
ownership of the control program through increasing government
funding and support to the NTDCP activities and to mobilize
resources from existing and potential partners. At sub-country
level, advocacy activities were focused on mobilizing support from
local authorities at the regional, district and community levels.
Before each campaign, an official notice was sent by the
National Director of Health to all Regional Directors of Health to
inform them the mass treatment campaign and to request them to
achieve the objectives of the program. Several meetings between
the various stakeholders (Regional Directorates of Health, the
Regional Offices of Education, Social Development, local councils)
involved in the control of NTDs were conducted to galvanize
interest, support and participation in the campaign. Posters were
produced and sent to all health districts and radio and television
messages were broadcast to announce the mass treatment
campaign.
Figure 2. Endemic situation shown as number of major target NTDs in each district in Mali. LF: lymphatic filariasis; ONCH: onchocerciasis;
SCH: schistosomiasis; STH: soil-transmitted helminthiasis; TRA: trachoma. In Kidal region, the endemicity level of schistosomiasis in each district is not
yet clear and further mapping is planned.
doi:10.1371/journal.pntd.0001574.g002
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ties during mass treatment campaign. Images of severe cases of
each of the five NTDs were shown, including the short-and long-
term signs and symptoms and the treatment available. These
meetings also served as means of motivating communities to
participate in the mass treatment campaign. These meetings also
proved to be effective in mobilizing funds to support CDDs in
some districts.
Figure 3. Drug packages required for each district according to the WHO PCT guidelines. MDA1: ivermectin+albendazole; T2:
praziquantel, ZTM: Zithromax. In Kidal region the endemicity level of schistosomiasis in each district is not yet clear and further mapping is planned.
doi:10.1371/journal.pntd.0001574.g003
Table 1. Number of persons trained under the integrated NTD control program (10.2007–03.2011).
Categories of trainees Number of persons trained
Ministry of Health staff at central level 10
Trainers 373
Supervisors (CHCWs) 3,386
CDDs 81,194
Other ( staff from Academies of Teaching, Pedagogic Center of Animation, Social
Development Services, NGOs in health sector, interviewers for surveys)
1,285
TOTAL 86,248
doi:10.1371/journal.pntd.0001574.t001
Neglected Tropical Disease Control in Mali
www.plosntds.org 6 March 2012 | Volume 6 | Issue 3 | e1574Behavior change communications
Behavior change communication has been a very important
part in the Mali integrated NTD control program. A workshop to
develop and harmonize health messages was organized each year.
It was followed by the development of audiovisual materials.
These messages were broadcast on the various channels during the
month immediately preceding the campaigns, and throughout the
duration of the campaigns. Posters and banners were also posted
strategically during the course of the weeks preceding the
campaign. Short documentaries on NTDs and mass treatment
campaigns were broadcast on television at least three times during
the 20 days preceding the campaign as well as during the
campaign. The same schedule was used for broadcasting the radio
messages.
Counseling cards on the five NTDs were designed and these
cards are used by the CDDs during mobilization and drug
distribution to educate people about the disease and the
importance of treatment. The cards also contained information
for communities to understand the behaviors that could cause or
complicate these diseases and the behaviors that could help
prevent them from getting the diseases, such as hand washing and
face washing. To date, 3,000 counseling cards and 500 posters
have been produced.
Data collection and analysis
Data on treatment and serious adverse events (SAEs) in this
paper were the CDD-reported data from the NTDCP. During the
mass treatment campaign, the CDDs recorded data on drug
usage, treatment numbers and SAEs using specific reporting
forms. The data were reported to national NTDCP through health
reporting system. In 2009, the reported coverage data were
verified through a post-PCT coverage survey (details not shown
here). In the current paper, to standardize the calculation for all
targeted NTDs, national census population was used and
population at risk for each NTD was estimated according to the
annual projected population figures from the National Directorate
of Population, Mali. Eligible population was estimated as the total
population at risk for trachoma and 80% of the total population at
risk for LF, onchocerciasis, schistosomiasis and STH. The
coverage rates were calculated according to the WHO guidelines
for drug coverage monitoring, including geographical coverage,
program coverage and national coverage [23]. The geographical
coverage is the percentage proportion of the targeted districts
among the total number of endemic districts for each disease. The
program coverage is the percentage proportion of the population
treated among the eligible population in the targeted program
areas. The national coverage is the percentage proportion of the
population treated among the total population at risk in the
country.
The cost data were from the HKI program accounts specific for
direct expenditure in Mali on the NTD program activities. HKI
receives expense receipts after completion of each activity from the
NTDCP. The original receipts for all expenses are maintained by
HKI, and are spot checked during internal financial reviews as
well as during HKI’s federally-mandated annual A-133 audit.
Expenses, such as vehicle fuel, per diems, and supplies etc. directly
incurred during the implementation of program activities, are
uniquely coded in HKI’s financial system based on the type of
activity supported (e.g. training of CDDs, drug transport and
distribution, etc.). On a monthly basis, all program expenses are
categorized by activities based on these unique codes, and a
running cost total is maintained for each activity over the life of the
project.
Results
Scale-up of geographical coverage
The integrated MDA activities started in 2007. To gain
experience of the integrated delivery of different drug packages
by the CDDs, the integrated drug delivery started in three regions
(Kayes, Koulikoro and Sikasso) which included 24 districts. It was
then gradually scaled up to include more regions in the following
years to achieve national coverage in 2009. The number of
districts covered by MDA each year since 2005 and the cumulative
coverage are summarized in Table 2. Onchocerciasis MDA
achieved 100% geographical coverage before 2007 and this has
been maintained since. Trachoma MDA started in two regions
(Kayes and Koulikoro) and already met the program target after
three rounds of treatment before 2007. It was gradually expanded
to include all other endemic regions in 2009. The significant gain
of the integrated NTD program was the scale-up for LF MDA
which achieved full national geographic coverage in 2009, and this
has since been maintained. The national coverage of LF MDA
also benefited STH control throughout the country. MDA for
schistosomiasis achieved national coverage for school-age children
in 2007, and each endemic district had been targeted two to five
times by the end of 2010 according to the endemicity level. In the
scarcely populated Kidal region, the mapping of schistosomiasis in
this region was not conducted due to the insecurity and will be
done later. MDA for schistosomiasis targeting school-age children
in this region was delivered based on the historical and clinical
knowledge.
Scale up of program coverage
With gradual scale-up of geographical coverage, the number of
people targeted and treated/retreated each year increased
noticeably. The annual treatment numbers for each targeted
NTD and the percentage coverage (program coverage and
national epidemiological coverage) rates are shown in Table 3
(including data from 2005–06 before integration). Overall,
satisfactory program coverage rates had been achieved each year
in the targeted areas since 2007 and maintained at high level since
2009, with those for LF, onchocerciasis, STH and trachoma
ranging from 76% to over 100%. Although overall program
Table 2. Number of districts targeted annually for MDA for
each disease since 2005.
Diseases 2005 2006 2007 2008 2009 2010 2011
a
LF 4
(6.8)
c
15
(25.4)
24
(40.7)
35
(59.3)
59
(100)
59
(100)
60
b
(100)
Onchocerciasis 16
(100)
16
(100)
16
(100)
16
(100)
16
(100)
16
(100)
17
b
(100)
Schistosomiasis 31
(58.5)
40
(75.5)
28
(100)
45
(100)
27
(100)
49
(100)
23
(100)
STH 31
d
(52.5)
40
d
(67.8)
24
(78)
35
(86.4)
59
(100)
59
(100)
60
b
(100)
Trachoma 19
(38)
24
(64)
8
(80)
29
(90)
38
(100)
23
(100)
10
(100)
a2011 MDA was still ongoing during drafting of this paper so these are
projected figures.
bSikasso district in the original 59 was split into two districts to become a total
of 60 districts.
cFigures in brackets represent the cumulative geographical coverage.
dFigures include the districts where schoolchildren were treated with ALB
together with schistosomiasis MDA.
doi:10.1371/journal.pntd.0001574.t002
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program coverage rates had been high among school-age children,
the main targeted group according to the WHO recommenda-
tions. Most notably, the national epidemiological coverage for LF
steadily increased over the years to reach over 65%, treating
around 10 million people each year since 2009, and this also
benefited STH control throughout the country with national
epidemiological coverage of 66–75%.
Severe adverse effects
Some minor side effects from taking the drugs had been
recorded such as diarrhea and headaches and these were usually
dealt with at the community health centers. However, no cases
with severe adverse effects have been recorded so far.
Cost of the program
The total direct cost of the program in Mali is $3.575 million
from the start of the program in 2007 to March 2011, which
covers four rounds of drug delivery. The cost shown here does not
include the significant contribution from the MoH on housing,
logistics, staff salaries etc., and the cost of drugs, which were either
donated free of charge or directly procured by RTI. It also does
not include any opportunity costs and monetary contributions
from local governments, for example, in 2010 the Kayes mayor’s
office donated an amount of five million francs (CFA) to help
motivate the CDDs during the campaign. As expected, the major
expenditures were for MDA activities which included training of
CDDs, drug transport, storage and administration, and M&E,
supervision and annual program reviews (Figure 4).
Discussion
The concept of integration was to increase efficiency and
treatment coverage to deliver the drugs to those who are in need.
Since the injection of major funds from the USAID for the
integrated NTD control activities, Mali has significantly scaled up
MDA coverage for all five targeted major NTDs. Apart from the
success in onchocerciasis control already achieved, national
geographical coverage has been achieved for LF from 25% in
2006 to 100% in 2009, reaching national coverage of over 65%.
After completion of four rounds of MDA, a sentinel site study was
conducted in Sikasso and Koulikoro regions in 2010, and will be
conducted in other regions accordingly when the criteria are met
in each region. The results will be published separately once
enough data are collected. Such national coverage of treatment
with ALB and IVM for LF greatly benefits the STH control
throughout the country. It also continues to benefit the
onchocerciasis elimination in the original 16 districts at risk for
onchocerciasis. A recent publication from multi-center studies
including the Bakoye river focus in Mali showed that the
prevalence of onchocerciasis had been reduced to below 1% by
14 years of annual treatment, which confirmed the feasibility of
Table 3. Annual number of persons treated and treatment coverage for the targeted NTDs.
2005 2006 2007 2008 2009 2010
a
LF
No of persons treated 511,416 2,216,705 4,527,977 5,445,651 9,762,073 10,047,125
Program coverage (%) 103.9 97.6 94.9 84.7 91.5 91.1
National coverage (%) 4.4 18.5 36.8 43.1 75.3 66.8
Onchocerciasis
No of persons treated 1,587,000 1,734,586 1,635,416 1,701,300 3,069,804 3,387,412
Program coverage (%) 101.8 101.6 94.5 78.7 103.8 90.0
National coverage (%) 39.6 42.2 38.7 39.3 69.0 65.9
Trachoma
No of persons treated 3,334,845 5,383,845 1,767,877 5,537,302 6,416,637 3,145,826
Program coverage (%) 79.8 104.9 78.6 76.2 78.5 97.2
National coverage (%) 32.4 51.2 16.5 50.4 57.2 23.9
Schistosomiasis
No of persons treated 2,598,138 2,174,940 895,343 2,551,995 1,796,586 4,526,684
(No of SAC
b treated) (1,948,964) (1,627,240) (384,104) (1,468,410) (1,148,733) (2,704,918)
Program coverage (%) 50.0 40.1 47.8 58.2 71.4 69.5
(Program coverage SAC
(%))
(99.0) (80.8) (72.7) (100.7) (92.9) (88.8)
National coverage (%) 22.2 18.1 7.3 20.2 13.9 30.1
(National coverage SAC
(%))
(55.6) (45.2) (10.4) (38.8) (29.5) (60.0)
STH
No of persons treated 2,598,138 2,174,940 4,427,977 5,445,651 9,762,073 10,047,125
Program coverage (%) 48.8 40.5 94.9 84.7 91.5 91.1
National coverage (%) 22.2 18.1 36.8 43.1 75.3 66.8
aPopulation in 2010 was projected according to the 2009 census while populations for previous years were projected according to the 2000 census.
bSAC – school-age children.
doi:10.1371/journal.pntd.0001574.t003
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areas are to be conducted, and Mali is on track to achieve the
objective of elimination of onchocerciasis as public health problem
which has recently been adopted by the African Program for
Onchocerciasis Control as the program objective of onchocerciasis
control in Africa [25].
Trachoma control is one of the most successful control
programs in the country. Since integration, program coverage
rates for trachoma have been very high, ranging from 76% to
97%. The PNLC through the NTDCP has made great progress
with determining which districts no longer warrant treatment at
district level by conducting impact studies after three to four
consecutive rounds of treatment with Zithromax and tetracycline
ointment. Currently only 10 districts in the five regions of Gao,
Kidal, Koulikoro, Kayes, and Segou still warrant for MDA at
district level. The PNLC is working with WHO, HKI, and the
Carter Center to pilot a post-endemic surveillance protocol in the
districts where trachomatous follicular (TF) prevalence has fallen
below 5%. The relatively low annual national coverage for
trachoma shown here was mainly due to the progressive starting of
the MDA among districts and stopping of MDA in districts that no
longer required treatment.
Treatment with PZQ for schistosomiasis at a national level has
reached all eight regions plus Bamako with overall program
coverage rates ranging from 40% to around 70%. The target
population for schistosomiasis treatment in Mali has been primarily
school-age children and adults at high risk. Program coverage in
school-age children has been maintained over 80% except 72.7% in
2007. According to the WHO guidelines [4], not every district and
child require annual treatment, therefore the annual national
coverage rates shown here looked relatively low, even though the
program coverage for school-age children each year was high. In
addition to the USAID funding, Mali also receives support from
other partners in country, such as the Organization for the
Maintenance of the River Senegal (OMVS) and World Vision
International (WVI), whose funds helped to procure PZQ and
support distribution costs in the regions of Kayes and Koulikoro.
Integration of vertical national control programs was complex
and challenging [26]. As one of the first five ‘fast-track’ countries
to implement the integrated program without prior examples to
follow, Mali designed and adopted the implementation strategies
according to the local context. The program was coordinated by
the national NTDCP team and at the local level it was integrated
into the primary health care system. The NTD control became a
routine activity of the CHCWs. There was a concern that
involvement of the CHCWs would impact on their time in
responding to curative cares hence interrupting the service
provision at the local health facilities [27]. This may have been
the case at the beginning of the program; however, this approach
would provide the best chance for long-term sustainability of NTD
controls [3,28]. Over 3000 CHCWs countrywide have been
trained and retrained, who will be able to provide quality health
services at health centers for NTDs once the large-scale MDA is
scaled down when the short-term objectives are met. In reality, it is
anticipated that such a large-scale intervention would have
reduced the demand of the CHCWs’ time due to the reduction
of morbidity reverted by MDA [29,30].
Despite the progress of the NTD control program and
achievements made, there are a number of difficulties/challenges
still in the program and lessons learnt:
1) For the long-term sustainability, the program is integrated
with the primary health care system at the local level. At this
level there are many overlapping public health campaigns
that occur at the same time as the MDA, such as national
immunization days. Competition for the CHCW and CDD
time is high, which means possible delay for one program or
another. Better coordination is needed, perhaps further
integration of MDA. A study has been carried out to use the
SIAN program as a possible platform for MDA. A further
combination of drugs may also reduce the need of CHCW
and CDD time by reducing the number of drug packages
and rounds of drug delivery. A number of studies showed
that combining ALB, IVM and PZQ caused no more severe
adverse effect than the current drug combinations [31,32],
and such further combination will be considered in the
future MDAs as experience has been gained by the CDDs.
Study on combining Zithromax with ALB and IVM is also
underway in Mali, which will pave the way for further
combination in non-schistosomiasis MDA areas.
Figure 4. Percentage expenditure of the NTD program activities for the first four rounds of MDA.
doi:10.1371/journal.pntd.0001574.g004
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increasingly become a challenge. It is difficult to retain
CDDs without financial incentives for NTD programs while
other programs e.g. those for malaria and HIV/AIDS are
paying them. Traditional kinship structure has successfully
been used to enhance the MDA for onchocerciasis in
Uganda [34]. As mentioned earlier, the Kayes mayor’s
office set an example in donating funds to help motivate the
CDDs during the campaign, and such local contributions
may be sought in future in other regions.
3) Withthecurrentdrugdonationmechanismsinvolvingmultiple
donors and multiple levels of drug management, delay in drugs
reaching the country for distribution has been a challenge and
may remain so in near future. Such delay often causes MDA
postponed into rainy season, which not only increases the
difficulty in the campaign but also minimize the impact of
MDA, particularly for schistosomiasis. Forward planning and
drug procurement at the country program level is necessary to
overcome such obstacles. The NTDCP has therefore now
decided to revise its annual program so that all the key events
are scheduled to take place earlier than previously or usually
planned. The annual review, which usually takes place in
November, will now take place at the end of September. This
will enable to the program to get the final MDA results earlier
and, as a result, to place drug orders earlier.
4) For a long-term, sustainable control/elimination of NTDs,
comprehensive measures are needed. The current NTD
funds are almost exclusively supporting the integrated
MDA. Case management, clean water supply, hygiene and
sanitation, and vector management etc. are all critical
components of a control program in order to achieve and
maintain the long-term program objectives. The NTDCP
received funds from Conrad N Hilton Foundation through
HKI and the Carter Center to implement the S, F and E
components of the trachoma SAFE strategy, but so far are
struggling to find funds to support the non-MDA compo-
nents for other NTDs.
5) Funds are available for the monitoring and evaluation on the
impact achieved for LF and trachoma, but there are
insufficient funds to support similar activities for other three
targeted NTDs. As described, Mali has conducted several
rounds of integrated MDA for onchocerciasis, schistosomiasis
and STH. There is a need to reassess the prevalence level
throughout the country in order to adjust the MDA strategy.
6) It has been a challenge to collect data from all districts after
each MDA in a timely fashion. Nationally the integrated
MDA is a long campaign each year lasting around five
months from training to national annual review. Any delay
in collecting data from each district will affect the annual
planning for the next year. A successful pilot trial using
mobile phone text messages to report the MDA data was
conducted in a number of districts. This may be expanded in
the country to expedite the data reporting in future.
7) Inventory keeping and re-stocking of residual drugs after
MDA has been difficult. This resulted in significant loss of
residual drugs. The supply chain management needs to be
strengthened. Assistance from external consultants has been
sought, and it is hoped that the system should be improved
in next rounds of MDA.
8) Mali is a large country deep into the Sahara desert. It has
been a real challenge for the integrated MDA to reach
remote areas, particularly, nomadic populations in the
northern half of the country (e.g. Gao, Kidal, and
Tombouctou). These areas are also insecure which often
cause delay in MDA. To overcome these, the NTDCP used
various drug delivery strategies within the regions, particu-
larly e.g. the mobile teams (CDDs on motorbikes) to reach
those in need.
9) At the beginning of the program, local people had little
knowledge about NTDs and complications, and therefore
the compliance of MDA was low. The NTDCP used the
visual aids (posters, counseling cards etc.) containing pictures
of severe NTD cases, in particular LF and schistosomiasis, to
educate and mobilize the populations. The program also
involved the political leaders, religious leaders and village
chiefs in starting the MDA campaign. Their taking of the
drugs set a great example for community members to follow.
Conclusions
Built on the existing success of individual national control
programs, the Government of Mali has shown commitment in the
control of NTDs in the country. The coordination of NTD control
has been integrated at the central level and implementation
activities are integrated with the primary health care system at the
local communities. With the financial support from the USAID
and other donors, Mali has scaled up the drug treatment to a
national coverage through integrated drug delivery, with around
10 million people receiving one or more drug packages each year
since 2009. With the progress of the program, the focus is now on
consolidating the achievements to achieve the goals of eliminating
LF and blinding trachoma, perhaps also onchocerciasis, and
reducing the morbidity caused by schistosomiasis and STH, in the
country by the preset timelines, and on mobilizing resources for
the next phase of the NTD control according to the new national
strategic plan. Mali’s successes and lessons learned can be valuable
assets to other countries starting up their integrated national NTD
control programs.
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